* Allakos Inc reported a quarterly adjusted loss of 81 cents per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of -49 cents. The mean expectation of nine analysts for the quarter was for a loss of 47 cents per share. Wall Street expected results to range from -64 cents to -36 cents per share.
* Reported revenue was zero; analysts expected zero.
* Allakos Inc's reported EPS for the quarter was a loss of 81 cents.
* The company reported a quarterly loss of $71.15 million.
* Allakos Inc shares had held steady so far this quarter and lost 53.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 7% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Allakos Inc is $2.00 This summary was machine generated from LSEG data May 9 at 10:04 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.47 -0.81 Missed
Dec. 31 2023 -0.47 -0.71 Missed
Sep. 30 2023 -0.45 -0.52 Missed
Jun. 30 2023 -0.48 -0.41 Beat
Comments